Minireview: Thioredoxin-interacting protein: Regulation and function in the pancreatic β-cell

Molecular Endocrinology

Volumn 28, Issue 8, 2014, Pages 1211-1220

  Shalev, Anath ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; MICRORNA; MICRORNA 17; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CARRIER PROTEIN; TXNIP PROTEIN, HUMAN;

APOPTOSIS; CELL SURVIVAL; CYTOLOGY; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; HUMAN; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL SURVIVAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS;

EID: 84905270049     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1095     Document Type: Review

References (113)

1. Chen KS, DeLuca HF. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta. 1994;1219:26-32
2. Ludwig DL, Kotanides H, Le T, Chavkin D, Bohlen P, Witte L. Cloning, genetic characterization, and chromosomal mapping of the mouse VDUP1 gene. Gene. 2001;269:103-112
3. Nishiyama A, Matsui M, Iwata S, et al. Identification of thioredoxin- binding protein-2/vitamin D3 up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem. 1999;274:21645-21650
4. Castellani LW, Weinreb A, Bodnar J, et al. Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. Nat Genet. 1998;18:374-377
5. Stassen AP, Groot PC, Eppig JT, Demant P. Genetic composition of the recombinant congenic strains. Mamm Genome. 1996;7:55-58
6. Groot PC, Moen CJ, Dietrich W, Stoye JP, Lander ES, Demant P. The recombinant congenic strains for analysis of multigenic traits: genetic composition. FASEB J. 1992;6:2826-2835
7. Bodnar JS, Chatterjee A, Castellani LW, et al. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet. 2002;30: 110-116
8. Sheth SS, Castellani LW, Chari S, et al. Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition. J Lipid Res. 2005;46:123-134
9. Hui TY, Sheth SS, Diffley JM, et al. Mice lacking thioredoxininteracting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem. 2004; 279:24387-24393
10. Pajukanta P, Lilja HE, Sinsheimer JS, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet. 2004;36:371-376
11. Nishiyama A, Masutani H, Nakamura H, Nishinaka Y, Yodoi J. Redox regulation by thioredoxin and thioredoxin-binding proteins. IUBMB Life. 2001;52:29-33
12. Junn E, Han SH, Im JY, et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol. 2000;164:6287-6295
13. Yamanaka H, Maehira F, Oshiro M, et al. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast twohybrid system. Biochem Biophys Res Commun. 2000;271:796-800
14. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT. The interaction of thioredoxin with Txnip: evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem. 2006;281: 21884-21891
15. Forrester MT, Seth D, Hausladen A, et al. Thioredoxin-interacting protein (Txnip) is a feedback regulator of S-nitrosylation. J Biol Chem. 2009;284:36160-36166
16. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem. 1989;264:13963-13966
17. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J Biol Chem. 1979;254:9627-9632
18. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17:2596-2606
19. Noguchi T, Takeda K, Matsuzawa A, et al. Recruitment of TRAF family proteins to the ASK1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem. 2005;280:37033-37040
20. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity- independent manner. Circ Res. 2002;90:1259-1266
21. Schulze PC, De Keulenaer GW, Yoshioka J, Kassik KA, Lee RT. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res. 2002;91:689-695
22. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem. 2004;279:30369-30374
23. Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem. 2010;285:3997-4005
24. Xu G, Chen J, Jing G, Shalev A. Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med. 2013;19:1141-1146
25. Patwari P, Chutkow WA, Cummings K, et al. Thioredoxin-independent regulation of metabolism by the α-arrestin proteins. J Biol Chem. 2009;284:24996-25003
26. Polekhina G, Ascher DB, Kok SF, Waltham M. Crystallization and preliminary X-ray analysis of the N-terminal domain of human thioredoxin-interacting protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011;67(Pt 5):613-617
27. Hwang J, Suh HW, Jeon YH, et al. The structural basis for the negative regulation of thioredoxin by thioredoxin-interacting protein. Nat. Commun. 2014;5:2958
28. Shalev A, Pise-Masison CA, Radonovich M, et al. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFβ signaling pathway. Endocrinology. 2002;143:3695-3698
29. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity inβ-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581-587
30. Mandrup-Poulsen T. β-cell apoptosis: stimuli and signaling. Diabetes. 2001;50 Suppl 1:S58-S63
31. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol. 2003;66:1433-1440
32. Bonner-Weir S. Life and death of the pancreatic β cells. Trends Endocrinol Metab. 2000;11:375-378
33. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47:358-364
34. Mathis D, Vence L, Benoist C. β-Cell death during progression to diabetes. Nature. 2001;414:792-798
35. Poitout V, Robertson RP. Minireview: Secondary β-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143:339-342
36. Minn AH, Hafele C, Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces β-cell apoptosis. Endocrinology. 2005;146:2397-2405
37. Chen J, Hui ST, Couto FM, et al. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic β-cell mass and protects against diabetes. FASEB J. 2008;22:3581-3594
38. Chen J, Fontes G, Saxena G, Poitout V, Shalev A. Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated β-cell death. Diabetes. 2010;59:440-447
39. Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxininteracting protein: a critical link between glucose toxicity and β-cell apoptosis. Diabetes. 2008;57:938-944
40. Spindel ON, World C, Berk BC. Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxid Redox Signal. 2012;16:587-596
41. Yoshihara E, Masaki S, Matsuo Y, Chen Z, Tian H, Yodoi J. Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol. 2014;4:514
42. 2+ influxmediated suppression of vitamin D3 up-regulated protein 1 (VDUP1) mRNA in cerebellar granule neurons undergoing apoptosis. J Neurochem. 2001;78:1267-1276
43. Kibbe C, Chen J, Xu G, Jing G, Shalev A. FOXO1 competes with carbohydrate response element-binding protein (ChREBP) and inhibits thioredoxin-interacting protein (TXNIP) transcription in pancreatic β cells. J Biol Chem. 2013;288:23194-23202
44. Xu G, Chen J, Jing G, Shalev A. Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes. 2012;61:848-856
45. Lerner AG, Upton JP, Praveen PV, et al. IRE1α induces thioredoxin- interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab. 2012;16:250-264
46. Wu N, Zheng B, Shaywitz A, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell. 2013;49:1167-1175
47. Shao W, Yu Z, Fantus IG, Jin T. Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (Tx- NIP) in pancreatic β-cells. Cell Signal. 2010;22:1240-1246
48. Robinson KA, Brock JW, Buse MG. Posttranslational regulation of thioredoxin-interacting protein. J Mol Endocrinol. 2013;50: 59-71
49. Cha-Molstad H, Saxena G, Chen J, Shalev A. Glucose-stimulated expression of Txnip is mediated by carbohydrate response element- binding protein, p300, and histone H4 acetylation in pancreatic β cells. J Biol Chem. 2009;284:16898-16905
50. Yamashita H, Takenoshita M, Sakurai M, et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A. 2001;98:9116-9121
51. Poungvarin N, Lee JK, Yechoor VK, et al. Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in β cell glucotoxicity. Diabetologia. 2012;55:1783-1796
52. Stoltzman CA, Peterson CW, Breen KT, Muoio DM, Billin AN, Ayer DE. Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc Natl Acad Sci U S A. 2008;105:6912-6917
53. Minn AH, Couto FM, Shalev A. Metabolism-independent sugar effects on gene transcription: the role of 3-O-methylglucose. Biochemistry. 2006;45:11047-11051
54. Svoboda M, Tastenoy M, Zhang Y, et al. D-Glucose and 3-Omethyl- D-glucose-induced upregulation of selected genes in rat hepatocytes and INS1E cells: reevaluation of the possible role of hexose phosphorylation. Mol Med Rep. 2013;8:829-836
55. Stoltzman CA, Kaadige MR, Peterson CW, Ayer DE. MondoA senses non-glucose sugars: regulation of thioredoxin-interacting protein (TXNIP) and the hexose transport curb. J Biol Chem. 2011;286:38027-38034
56. Shaked M, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. AMP-activated protein kinase (AMPK) mediates nutrient regulation of thioredoxin-interacting protein (TXNIP) in pancreatic β-cells. PLoS One. 2011;6:e28804
57. Reich E, Tamary A, Sionov RV, Melloul D. Involvement of thioredoxin- interacting protein (TXNIP) in glucocorticoid-mediated βcell death. Diabetologia. 2012;55:1048-1057
58. Lekva T, Bollerslev J, Sahraoui A, et al. Thioredoxin interacting protein is a potential regulator of glucose and energy homeostasis in endogenous Cushing's syndrome. PLoS One. 2013;8:e64247
59. Shaked M, Ketzinel-Gilad M, Ariav Y, Cerasi E, Kaiser N, Leibowitz G. Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E βcells and in Psammomys obesus pancreatic islets. Diabetologia. 2009;52: 636-644
60. Parikh H, Carlsson E, Chutkow WA, et al. TXNIP Regulates Peripheral Glucose Metabolism in Humans. PLoS Med. 2007;4: e158
61. Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2006;346:1067-1074
62. Chen J, Jing G, Xu G, Shalev A. Thioredoxin-Interacting Protein Stimulates its Own Expression via a Positive Feedback Loop. Mol Endocrinol. 2014;28:674-680
63. Hasegawa J, Osatomi K, Wu RF, Uyeda K. A novel factor binding to the glucose response elements of liver pyruvate kinase and fatty acid synthase genes. J Biol Chem. 1999;274:1100-1107
64. Wang H, Wollheim CB. ChREBP rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells. J Biol Chem. 2002;277:32746-32752
65. Davies MN, O'Callaghan BL, Towle HC. Glucose activates ChREBP by increasing its rate of nuclear entry and relieving repression of its transcriptional activity. J Biol Chem. 2008;283: 24029-24038
66. Kawaguchi T, Takenoshita M, Kabashima T, Uyeda K. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/ dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci U S A. 2001;98:13710-13715
67. Denechaud PD, Bossard P, Lobaccaro JM, et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest. 2008;118:956-964
68. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc Natl Acad Sci U S A. 2003;100:5107-5112
69. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive elementbinding protein by AMP-activated protein kinase. J Biol Chem. 2002;277:3829-3835
70. Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W, Accili D. FoxO1 protects against pancreatic βcell failure through NeuroD and MafA induction. Cell Metab. 2005;2:153-163
71. Buteau J, Accili D. Regulation of pancreatic β-cell function by the forkhead protein FoxO1. Diabetes Obes. Metab. 2007;9(suppl 2):140-146
72. Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes. 2006;55:1190-1196
73. Kawamori D, Kaneto H, Nakatani Y, et al. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem. 2006;281:1091-1098
74. Okamoto H, Hribal ML, Lin HV, et al. Role of the forkhead protein FoxO1 in _ cell compensation to insulin resistance. J Clin Invest. 2006;116:775-782
75. Oslowski CM, Hara T, O'Sullivan-Murphy B, et al. Thioredoxin interacting protein mediates ER stress-induced βcell death through initiation of the inflammasome. Cell Metab. 2012;16: 265-273
76. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 2006;13:363-373
77. Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM, Perera RJ. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004;32:e188
78. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129:1401-1414
79. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228-234
80. Zhuo de X, Niu XH, Chen YC, Xin DQ, Guo YL, Mao ZB. Vitamin D3 up-regulated protein 1(VDUP1) is regulated by FOXO3A and miR-17-5p at the transcriptional and post-transcriptional levels, respectively, in senescent fibroblasts. J Biol Chem. 2010;285:31491-31501
81. Minn AH, Pise-Masison CA, Radonovich M, et al. Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2005;336:770-778
82. Wang Y, De Keulenaer GW, Lee RT. Vitamin D3-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem. 2002; 277:26496-26500
83. Shalev A. Lack of TXNIP protects β-cells against glucotoxicity. Biochem Soc Trans. 2008;36(Pt 5):963-965
84. Corbett JA. Thioredoxin-interacting protein is killing my β-cells! Diabetes. 2008;57:797-798
85. Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208: 535-548
86. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011;301:H1798-H1809
87. Artner I, Hang Y, Mazur M, et al. MafA and MafB regulate genes critical to β-cells in a unique temporal manner. Diabetes. 2010; 59:2530-2539
88. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011; 91:795-826
89. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev. 2008; 29:303-316
90. Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A. Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through MIR-124A and FOXA2. J Biol Chem. 2014;289:11807-11815
91. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxininteracting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11:136-140
92. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327:296-300
93. Maedler K, Sergeev P, Ris F, et al. Glucose-induced β cell production of IL-1_ contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851-860
94. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle- Wells syndrome. Nat Genet. 2001;29:301-305
95. March CJ, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985;315:641-647
96. Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and β-cell dysfunction. Diabetes. 2014;63:1698-1711
97. Chutkow WA, Patwari P, Yoshioka J, Lee RT. Thioredoxin-interacting protein is a critical regulator of hepatic glucose production. J Biol Chem. 2008;283:2397-2406
98. Hotta M, Tashiro F, Ikegami H, et al. Pancreatic β cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med. 1998;188:1445-1451
99. Chou FC, Sytwu HK. Overexpression of thioredoxin in islets transduced by a lentiviral vector prolongs graft survival in autoimmune diabetic NOD mice. J Biomed Sci. 2009;16:71
100. Clee SM, Nadler ST, Attie AD. Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. Am J Ther. 2005; 12:491-498
101. Chutkow WA, Birkenfeld AL, Brown JD, et al. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes. 2010;59: 1424-1434
102. Yamamoto M, Yamato E, Toyoda S, et al. Transgenic expression of antioxidant protein thioredoxin in pancreatic β cells prevents progression of type 2 diabetes mellitus. Antioxid Redox Signal. 2008;10:43-49
103. Afzal N, Ganguly PK, Dhalla KS, Pierce GN, Singal PK, Dhalla NS. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes. 1988;37:936-942
104. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006;98:890-894
105. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients-findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151:1072-1079
106. Xiang G, Seki T, Schuster MD, et al. Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem. 2005;280:39394-39402
107. Yoshioka J, Chutkow WA, Lee S, et al. Deletion of thioredoxininteracting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest. 2012;122:267-279
108. Cha-Molstad H, Xu G, Chen J, et al. Calcium channel blockers act through nuclear factor Y to control transcription of key cardiac genes. Mol Pharmacol. 2012;82:541-549
109. Chen J, Cha-Molstad H, Szabo A, Shalev A. Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab. 2009;296:E1133-E1139
110. Shi Y, Ren Y, Zhao L, et al. Knockdown of thioredoxin interacting protein attenuates high glucose-induced apoptosis and activation of ASK1 in mouse mesangial cells. FEBS Lett. 2011;585:1789-1795
111. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010;1:e65
112. Sheth SS, Bodnar JS, Ghazalpour A, et al. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene. 2006;25:3528-3536
113. Oka S, Liu W, Masutani H, et al. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. FASEB J. 2006;20:121-123.